Biofrontera Expands the Patent Protection for Its Compound BF-1 in Migraine Prophylaxis

March 6, 2008 - Biofrontera AG (DSF: B8F) today announces that the Russian and Chinese patent offices have issued a patent for the migraine-prophylaxis compound BF-1. The patents protect the use of this substance as a pharmaceutical product in these countries. Biofrontera is currently developing this compound for the use in migraine prophylaxis. The two patents granted now expand the scope of protection for BF-1, which already entailed the whole of Europe, South Africa, and the USA. The issue of the patent in Hong Kong is awaited in the near future. Patents for Australia, Japan, Canada, Korea and India are pending.